The 10-second takeaway
For the quarter ended Sep. 30 (Q2), PetMed Express beat slightly on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share expanded.
Gross margins dropped, operating margins expanded, net margins increased.
PetMed Express reported revenue of $58.1 million. The seven analysts polled by S&P Capital IQ predicted sales of $57.2 million on the same basis. GAAP reported sales were 0.1% lower than the prior-year quarter's $58.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.20. The six earnings estimates compiled by S&P Capital IQ anticipated $0.17 per share. GAAP EPS of $0.20 for Q2 were 5.3% higher than the prior-year quarter's $0.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 33.3%, 90 basis points worse than the prior-year quarter. Operating margin was 10.9%, 50 basis points better than the prior-year quarter. Net margin was 6.9%, 20 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $47.9 million. On the bottom line, the average EPS estimate is $0.16.
Next year's average estimate for revenue is $229.1 million. The average EPS estimate is $0.72.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 875 members out of 904 rating the stock outperform, and 29 members rating it underperform. Among 208 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 199 give PetMed Express a green thumbs-up, and nine give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on PetMed Express is hold, with an average price target of $9.50.
Can your portfolio provide you with enough income to last through retirement? You'll need more than PetMed Express. Learn how to maximize your investment income and get "The 3 DOW Stocks Dividend Investors Need." Click here for instant access to this free report.
- Add PetMed Express to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.